Viking Therapeutics, Inc.

NASDAQ (USD): Viking Therapeutics, Inc. (VKTX)

Last Price

50.80

Today's Change

+0.92 (1.84%)

Day's Change

49.87 - 51.92

Trading Volume

2,640,957

Profile
VKTX

Exchange:  NASDAQ Capital Market NASDAQ Capital Market

Currency:  USD USD

Sector:  Healthcare - Healthcare Healthcare - Healthcare

Industry: 

CEO:  Dr. Brian Lian Ph.D. Dr. Brian Lian Ph.D.

Full Time Employees:  30 30

IPO Date:  2015-04-28 2015-04-28

CIK:  0001607678 0001607678

ISIN:  US92686J1060 US92686J1060

CUSIP:  92686J106 92686J106

Beta:  0.99 0.99

Last Dividend:  0.00 0.00

Dcf Diff:  50.22 50.22

Dcf:  0.58 0.58

Description

Viking Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of novel therapies for metabolic and endocrine disorders. The company's lead drug candidate is VK2809, an orally available tissue and receptor-subtype selective agonist of the thyroid hormone receptor beta (TRß), which is in Phase IIb clinical trials to treat patients with biopsy-confirmed non-alcoholic steatohepatitis, as well as NAFLD. It also develops VK5211, an orally available non-steroidal selective androgen receptor modulator that is in Phase II clinical trials for the treatment of patients recovering from non-elective hip fracture surgery; VK0612, an orally available Phase IIb-ready drug candidate for type 2 diabetes; and VK0214, an orally available tissue and receptor-subtype selective agonist of the TRß for X-linked adrenoleukodystrophy. The company was incorporated in 2012 and is headquartered in San Diego, California.

Address

9920 Pacific Heights Boulevard,
San Diego, CA 92121, US

858 704 4660

http://www.vikingtherapeutics.com

Discussions
Be the first to like this. Showing 0 of 0 comments

Post a Comment